Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418595 | 0.94 | HTR7 (0.45) | L3MBTL1HSD11B1TSHRKMT2APOLB | |
| SCHEMBL5433869 | 0.92 | POLB (0.43) | L3MBTL1HSD11B1TSHRKMT2APOLB | |
| SCHEMBL5425193 | 0.92 | SLC13A5 (0.40) | L3MBTL1HSD11B1TSHRKMT2APOLB | |
| SCHEMBL5421695 | 0.92 | USP2 (0.45) | L3MBTL1HSD11B1TSHRKMT2APOLB | |
| SCHEMBL5418435 | 0.92 | LMNA (0.51) | HSD11B1TSHRKMT2APOLBMEN1 | |
| SCHEMBL5438826 | 0.89 | LIPE (0.38) | L3MBTL1HSD11B1TSHRKMT2APOLB | |
| SCHEMBL5420449 | 0.89 | LIPE (0.60) | KMT2AMEN1LIPE | |
| SCHEMBL5429692 | 0.89 | LIPE (0.46) | TSHRKMT2APOLBMEN1LIPE | |
| SCHEMBL5427031 | 0.85 | CYP3A4 (0.55) | L3MBTL1TSHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5431071 | 0.85 | CYP3A4 (0.46) | L3MBTL1TSHRKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | ONO PHARMACEUTICAL CO., LTD. | 2007-11-29 | — | — | US | claimed |
| US-20070275990-A1 | Heterocyclic Spiro Compound | ONO PHARMACEUTICAL CO., LTD. | 2007-11-29 | — | — | US | disclosed |
| EP-1683797-A1 | HETEROCYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | NR3C2, CBR1, CBR3 | L3MBTL1 1548/4885HSD11B1 21/4885TSHR 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.